SciClone Pharma - Comparative Multiple Analysis

SciClone Pharma (Comparative Multiple Analysis)

placeholder_large_analysis.png
Banner%20-%20The%20perfect%20tool%20for%20investors%281%29.gif

Notes on the Comparative Multiple Analysis of SciClone Pharma

WikiWealth compares SciClone Pharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with SciClone Pharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for SciClone Pharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to SciClone Pharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for SciClone Pharma's Analysis


How does this work? The Comparative Investment Analysis determines the value of SciClone Pharma by comparing SciClone Pharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of SciClone Pharma.

See the SciClone Pharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in SciClone Pharma.

Also, see the SciClone Pharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and SciClone Pharma's valuation conclusion for a quick summary.